Christina L Wassel1, Cecilia Berardi2, James S Pankow3, Nicholas B Larson4, Paul A Decker4, Naomi Q Hanson5, Michael Y Tsai5, Michael H Criqui6, Matthew A Allison6, Suzette J Bielinski2. 1. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: cwassel@pitt.edu. 2. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 4. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 5. Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, MN, USA. 6. Division of Preventive Medicine, Department of Family and Preventive Medicine, University of California - San Diego, La Jolla, CA, USA.
Abstract
OBJECTIVE: To determine the association of circulating P-selectin with prevalent and incident peripheral artery disease (PAD), the ankle brachial index (ABI), and change in the ABI. METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective population-based cohort study including 6814 European descent, African American, Hispanic and Chinese men and women aged 45-84 at baseline. Four clinical exams took place after the baseline exam. After excluding those with ABI>1.4, prevalent and incident PAD were defined as an ABI≤0.90. ABI progression was defined as progression from a normal ABI (0.91-1.4) to abnormal (≤0.90 or >1.4) at a later exam. RESULTS: In adjusted models, each SD (13 ng/mL) higher P-selectin was significantly associated with 0.007 lower ABI (95% CI ((-0.011, -0.004)), p < 0.001), and an average change in the ABI of -0.006 ((-0.010, -0.003, p < 0.001). P-selectin was significantly associated with a 1.17-fold greater odds of prevalent PAD ((1.02, 1.33), p = 0.03), and a 30% greater risk of incident PAD ((1.11, 1.53), p = 0.001), as well as progression from a normal ABI to an ABI≤ 0.90 (p = 0.003), but not to an ABI>1.4 (p = 0.96). Addition of P-selectin to models containing traditional PAD risk factors and markers of inflammation/coagulation significantly improved the net reclassification for ABI progression (p = 0.03), but was only marginally significant for incident PAD (p = 0.06). CONCLUSIONS: P-selectin is significantly associated with the development of PAD. However, further research is needed in population-based studies to confirm prospective associations of P-selectin with incident PAD and change in the ABI, as well as its potential predictive ability.
OBJECTIVE: To determine the association of circulating P-selectin with prevalent and incident peripheral artery disease (PAD), the ankle brachial index (ABI), and change in the ABI. METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective population-based cohort study including 6814 European descent, African American, Hispanic and Chinese men and women aged 45-84 at baseline. Four clinical exams took place after the baseline exam. After excluding those with ABI>1.4, prevalent and incident PAD were defined as an ABI≤0.90. ABI progression was defined as progression from a normal ABI (0.91-1.4) to abnormal (≤0.90 or >1.4) at a later exam. RESULTS: In adjusted models, each SD (13 ng/mL) higher P-selectin was significantly associated with 0.007 lower ABI (95% CI ((-0.011, -0.004)), p < 0.001), and an average change in the ABI of -0.006 ((-0.010, -0.003, p < 0.001). P-selectin was significantly associated with a 1.17-fold greater odds of prevalent PAD ((1.02, 1.33), p = 0.03), and a 30% greater risk of incident PAD ((1.11, 1.53), p = 0.001), as well as progression from a normal ABI to an ABI≤ 0.90 (p = 0.003), but not to an ABI>1.4 (p = 0.96). Addition of P-selectin to models containing traditional PAD risk factors and markers of inflammation/coagulation significantly improved the net reclassification for ABI progression (p = 0.03), but was only marginally significant for incident PAD (p = 0.06). CONCLUSIONS:P-selectin is significantly associated with the development of PAD. However, further research is needed in population-based studies to confirm prospective associations of P-selectin with incident PAD and change in the ABI, as well as its potential predictive ability.
Authors: M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner Journal: N Engl J Med Date: 1992-02-06 Impact factor: 91.245
Authors: Z J Zheng; A R Sharrett; L E Chambless; W D Rosamond; F J Nieto; D S Sheps; A Dobs; G W Evans; G Heiss Journal: Atherosclerosis Date: 1997-05 Impact factor: 5.162
Authors: Helaine E Resnick; Robert S Lindsay; Mary McGrae McDermott; Richard B Devereux; Kristina L Jones; Richard R Fabsitz; Barbara V Howard Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Ramin Shadman; Michael H Criqui; Warner P Bundens; Arnost Fronek; Julie O Denenberg; Anthony C Gamst; Mary M McDermott Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Mindy M Pike; Nicholas B Larson; Christina L Wassel; Kevin P Cohoon; Michael Y Tsai; James S Pankow; Naomi Q Hanson; Paul A Decker; Cecilia Berardi; Kristine S Alexander; Mary Cushman; Neil A Zakai; Suzette J Bielinski Journal: Thromb Res Date: 2017-02-24 Impact factor: 3.944
Authors: Tamar S Polonsky; Hongyan Ning; Martha L Daviglus; Kiang Liu; Gregory L Burke; Mary Cushman; John Eng; Aaron R Folsom; Pamela L Lutsey; Jennifer A Nettleton; Wendy S Post; Ralph L Sacco; Moyses Szklo; Donald M Lloyd-Jones Journal: J Am Heart Assoc Date: 2017-03-20 Impact factor: 5.501